title: High-Affinity PD-1 Protein Has Potential.
abstract: A small, engineered protein that selectively binds to PD-L1 with very high affinity was more effective in shrinking tumors in preclinical studies than existing antibody-based immune checkpoint inhibitors, and it may overcome some the drawbacks of these agents, according to data presented at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
mesh_terms: D000818:Animals; D002352:Carrier Proteins / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011485:Protein Binding; D015202:Protein Engineering
chemical_list: D002352:Carrier Proteins; D061026:Programmed Cell Death 1 Receptor